Subscribe to:
Post Comments (Atom)
skip to main |
skip to sidebar
Viral Matters focuses on all aspects of Direct Acting Antivirals (DAA) and Antiretrovirals in development and on the market.
Pages
Search This Blog
About Me
- Chris Barnes
- Redondo Beach, CA, United States
- A 17 year veteran of Medical Affairs and Commercial functions of the biopharma and pharmaceutical industry, with expertise in Hepatitis and HIV. christopherjbarnes10@gmail.com
Posts
Followers
Blog Archive
-
▼
2010
(110)
-
▼
September
(8)
- Excerpts from a "Hepatology" commentary on the fut...
- First micro-RNA-Targeted Drug to treat HCV enters ...
- FDA issues draft guidelines for STAT-C/DAA develop...
- LabCorp Enhances HCV Testing Services with the Lau...
- Viral Matters on Twitter & LinkedIn...
- The Street speaks: Forbes article on Vertex lead o...
- Idenix compounds put on 'clinical hold' after thre...
- Inhibitex completes phase 1a trial of nucleotide p...
-
▼
September
(8)
No comments:
Post a Comment